PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro.
about
Tick Bioactive Molecules as Novel Therapeutics: Beyond Vaccine TargetsThe renaissance of complement therapeutics.The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties.Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
P2860
PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
PASylated Coversin, a C5-Speci ...... i-Hemolytic Activity in Vitro.
@en
PASylated Coversin, a C5-Speci ...... i-Hemolytic Activity in Vitro.
@nl
type
label
PASylated Coversin, a C5-Speci ...... i-Hemolytic Activity in Vitro.
@en
PASylated Coversin, a C5-Speci ...... i-Hemolytic Activity in Vitro.
@nl
prefLabel
PASylated Coversin, a C5-Speci ...... i-Hemolytic Activity in Vitro.
@en
PASylated Coversin, a C5-Speci ...... i-Hemolytic Activity in Vitro.
@nl
P1476
PASylated Coversin, a C5-Speci ...... i-Hemolytic Activity in Vitro.
@en
P2093
Christoph Q Schmidt
Nadine Kuhn
P304
P356
10.1021/ACS.BIOCONJCHEM.6B00369
P577
2016-09-06T00:00:00Z